Pfizer evaluates Isogenica’s technology
This article was originally published in Scrip
Pfizer is assessing Isogenica's CIS display technology for its ability to generate therapeutic peptide candidates. Financial details and therapeutic areas of the evaluation agreement were not disclosed. The CIS display technology rapidly identifies peptides, polypeptides and antibodies that bind with high affinity and specificity to any molecular target, making very large gene libraries. Earlier this month, Isogenica granted Centocor Research & Development the non-exclusive right to use the CIS display technology for the discovery of certain therapeutic proteins. Isogenica will receive multi-million pound initial licence fees over the first three years of the agreement and ongoing licence maintenance fees and milestones associated with the clinical development of products discovered through the technology. Dr Kevin FitzGerald, Isogenica's CEO, said that the company normally conducted research for other companies rather than licensing out the platform.